Form 4: Eli Lilly Director Acquires Shares Through Deferral Plan

Kimberly H. Johnson, a director at Eli Lilly & Co, acquired 11 shares of common stock through a deferral plan.

Summary

• Kimberly H. Johnson, a director at Eli Lilly & Co, acquired 11 shares of common stock on October 21, 2024.
• The shares were acquired at a price of $906.13 per share.
• The acquisition was made through the Lilly Directors' Deferral Plan, where the shares are deferred in lieu of cash compensation.
• The shares will be settled in common stock following Ms. Johnson's separation from service.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is generally viewed neutrally to slightly positive as it aligns director interests with shareholders.

Positives

• The acquisition of shares by a director may signal confidence in the company's future performance.

Future Outlook

The acquired shares will be settled in common stock following the reporting person's separation from service.

Industry Context

This is a routine filing related to director compensation and is common practice for publicly traded companies.

Comparison to Industry Standards

• Director share acquisitions through deferral plans are a common practice among large publicly traded companies like Eli Lilly.
• Many pharmaceutical companies such as Pfizer (PFE) and Merck (MRK) also utilize similar compensation structures for their directors.
• These plans are designed to align the interests of directors with those of long-term shareholders.

Stakeholder Impact

• The share acquisition has a minor positive impact on shareholders as it aligns director interests with the company's long-term performance.

Key Dates

Keywords

Eli Lilly, LLY, Director, Share Acquisition, Deferral Plan, Form 4, Insider Trading